Figure 6From: The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden Scatter Plot of Incremental Costs and QALYs for GIOP T −2.5/2 Fracture Cohort: Teriparatide vs. Bisphosphonate Treatment. Back to article page